ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Biotechnology · US
$1.14
+3.64%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 1.06x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -11.44x
- Price / sales
- —
- Price / cash flow
- -1.12x
Enterprise value
- Enterprise value
- $29.9M
- EV / sales
- —
- EV / EBITDA
- -0.61x
- EV / EBIT
- -0.60x
- Market cap
- $48.7M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026